3rd ESTRO Forum 2015 S79 GAFCHROMIC film (EBT3) measurements in anthropomorphic phantoms. Results: Comparing data both via gamma analysis method (3%, 3mm) and DVH comparison (between TPS and MC), a very good agreement between dose distributions estimated by MC, TPS and films was shown. In table are summarized the gamma analysis results.
The main differences between MC and TPS were detected in high and low density structures (bone and air cavities) where differences between dose to medium and dose to water (as it is computed by TPS) are highlighted. In a single plan, where the PTV included bone structures (CTV was contoured in soft tissue), a 3mm displacement along axial, coronal and sagittal direction was simulated. In figure DVHs before and after the shift are shown.
It is clear that the CTV coverage is not affected and the homogeneity in the CTV is guaranteed even if a lower than prescribed dose to medium was detected in the bone of the reference dose distribution. Conclusions: This work proposes a method to model in TOPAS a proton therapy PBS machine using commissioning measurements with no machine geometrical head description. This modeling lets the user to simulate a complete treatment plan having as the only input the DICOM file produced by the TPS. This gives the physicist a completely independent MC dose calculation algorithm. One of the most interesting features is that the dose distribution is given in terms of absolute dose and the comparison can be implemented with no dose-rescaling. It can be used to validate the dose distribution coming from TPS or, in a near future, as a patient-specific QA tool.
[1] Perl J et al. Purpose/Objective: In proton therapy protons are used to deliver radiation to a target. This promises higher dose conformality in comparison with regular radiotherapy techniques. Intensity Modulated Proton Therapy (IMPT) is a form of proton therapy, in which a pencil beam is used to cover the target. Because image guidance has an increasing role in radiotherapy and MRI is a prime candidate for this imaging, the dosimetric feasibility of IMPT in a magnetic field of 1.5 T and the effect on the generated dose distributions compared to those at 0 T is evaluated, using Monte Carlo simulations. Materials and Methods: To generate the IMPT plans, existing treatment planning software for the MR Linac was used with proton beamlets as input. Using the Monte Carlo software TOol for PArticle Simulation (TOPAS), proton beamlets were generated. First the interactions within a box of water were simulated, in order to analyze the shape of the Bragg Peak inside a 1.5 T magnetic field, compared to the one without a magnetic field. Next, three different sites were selected to generate IMPT plans for, based on DICOM data. The selected sites were a shallow and deep head-neck tumor and an artificial liver tumor. As input for the plans, beamlets from three intuitively selected gantry angles were generated, covering the target completely from every angle, both in a 0 T and 1.5T magnetic field. The generation of the plans was accomplished using dedicated, homemade software, based on an inverse optimization method. For all sites, the IMPT plans for a 0 T and a 1.5 T magnetic field were generated and analyzed, by comparison of the dose parameters and difference inside the target. Results: For a simulated 150 MeV proton beam in a water phantom, the shift of the Bragg Peak due to the magnetic field was 1.14 cm, which is in accordance to the analytical solution. A Gaussian fit for the lateral dose profile at the Bragg Peak gave σ = 0.36 cm both without and with a magnetic field. For the DICOM data, the dose distributions of the generated IMPT plans for two sites are shown in figures 1a and 1b and figures 1d and 1e. The mean dose difference is μ = -8.5 × 10 -3 Gy (σ = 0.14 Gy) for the shallow head-neck target, μ = -0.17 Gy (σ = 1.11 Gy) for the deep head-neck target (figure 1c) and μ = -0.34 Gy (σ = 0.62 Gy) for the liver target (figure 1f). The DVHs of the target were similar and the dose to the OARs, except the body, was negligible (figure 1g,h).
Conclusions:
This study shows that the generation of an IMPT plan in a magnetic field is feasible. The impact of the magnetic field is only on the curvature of the proton beam, which should be taken into account, but the resulting dose distributions are equivalent. It also shows that the introduced framework, which consists of Monte Carlo simulation combined with the use of an inverse optimization method, can be used to generate IMPT plans. These plans can be used in future dosimetric comparisons with IMRT, the MR Linac and conventional IMPT. Finally, it shows the dosimetric feasibility of IMPT in a 1.5 T magnetic field. Purpose/Objective: To compare the clinical benefit of robust optimized Intensity Modulated Proton Therapy (IMPT) with current photon radiotherapy (IMRT) and PTV-based IMPT for head and neck cancer (HNC) patients. The clinical benefit is quantified in terms of both Normal Tissue Complication Probability (NTCP) and target coverage in the case of setup and range errors. Materials and Methods: For 10 HNC patients, PTV-based IMRT (7 fields), robust optimized (minimax) and PTV-based IMPT (2, 3, 4, 5 and 7 fields) plans were tested on robustness, meaning that at least 98% of the CTVs had to receive ≥ 95% of the prescribed dose in 90% of the possible systematic setup and range error scenarios. Robust optimized plans differed from PTV-based plans in that they target the CTV and penalize possible error scenarios, instead of using the static isotropic CTV-PTV margin. Perturbed dose distributions of all plans were acquired by simulating in total 8060 setup (+/-2.5mm) and range error (+/-3%) combinations. Furthermore, NTCP models for xerostomia and dysphagia were used to estimate the clinical benefit of IMPT versus IMRT. Results: The robustness criterion was met in the IMRT and minimax IMPT plans in all error scenarios, but for PTV-based IMPT plans this was only the case in 4 out of 10 patients. The volumes receiving deficient dose were sometimes centrally situated in the CTV (Figure) , indicating that expansion of the CTV-PTV margin would not solve the underdosage. Mean doses to the major salivary glands and swallowing related organs at risk (OAR) were generally lower with minimax than with PTV-based IMPT. Xerostomia and dysphagia NTCP values calculated for IMRT plans were reduced by 16.4% (95% CI; 10.1-22.7%) and 9.9% (95% CI; 4.9-14.9%) with minimax IMPT in the 5 patients with the largest NTCP reductions. In the other 5 patients the average NTCP reduction was smaller (xerostomia: 4.7% (95% CI; 1.0-8.3%) ; dysphagia: 3.0% (95% CI; -0.2-6.2%). Increasing the number of fields did not contribute to plan robustness, but improved organ sparing. Conclusions: The clinical benefit in terms of NTCP of robust optimized (minimax) IMPT compared to IMRT is equal or even greater than that of PTV-based IMPT in head and neck patients. Furthermore, the target coverage of minimax IMPT plans in the presence of setup and range errors was comparable to that of current photon radiotherapy (IMRT) plans. 
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